Personalized immunotherapy with encapsulated cell technology: Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors

被引：0

作者：

Fernandez, E. ^{[1
]}

Vernet, R. ^{[2
]}

Charrier, E. ^{[3
]}

Migliorini, D. M. ^{[4
]}

Urwyler, M. ^{[2
]}

Belkouch, M-C. ^{[2
]}

Von Rohr, O. ^{[5
]}

Saingier, V. ^{[5
]}

Ancrenaz, V. ^{[5
]}

Grandjean, N. ^{[6
]}

Lafferma, E. ^{[6
]}

Lavalliere, E. ^{[6
]}

Rubin, O. ^{[7
]}

Villard, J. ^{[8
]}

Grogg, J. N. ^{[9
]}

Mach, N. ^{[10
]}

机构：

[1] HUG Hopitaux Univ Geneve, Dept Oncol, Geneva, Switzerland

[2] HUG Hopitaux Univ Geneve, Cell based Immunotherapy Lab, Oncol, Geneva, Switzerland

[3] UNIGE Univ Geneve, Cell Based Immunotherapy Iab, Oncol, Ctr Med Univ CMU, Geneva, Switzerland

[4] Hop Univ Geneve HUG, Oncol, Geneva, Switzerland

[5] HUG Hop Univ Geneve, Cell based Immunotherapy Lab, Oncol, Geneva, Switzerland

[6] HUG Hop Univ Geneve, Clin Res Unit, Oncol, Geneva, Switzerland

[7] HUG Hop Univ Geneve, Clin Cell Therapy Lab, Geneva, Switzerland

[8] Hop Univ Geneve, Clin Cell Therapy Lab, Geneva, Switzerland

[9] MaxiVax SA, R&D, Geneva, Switzerland

[10] HUG Hop Univ Geneve, Oncol, Geneva, Switzerland

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.888

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

762P

引用

页码：S891 / S891

页数：1

共 50 条

[41] First-in-Human Trial of the PI3Kβ-Selective Inhibitor SAR260301 in Patients With Advanced Solid Tumors
Bedard, Philippe L.
Davies, Michael A.
Kopetz, Scott
Juric, Dejan
Shapiro, Geoffrey I.
Luke, Jason J.
Spreafico, Anna
Wu, Bin
Castell, Christelle
Gomez, Corinne
Cartot-Cotton, Sylvaine
Mazuir, Florent
Dubar, Michel
Micallef, Sandrine
Demers, Brigitte
Flaherty, Keith T.
CANCER, 2018, 124 (02) : 315 - 324
[42] Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial)
Varga, Andreea
Baldini, Capucine
Martin-Romano, Patricia
Hollebecque, Antoine
Gazzah, Anas
Bahleda, Rastislav
Menis, Jessica
Champiat, Stephane
El-Dakdouki, Yolla
Paoletti, Xavier
Ribrag, Vincent
Michot, Jean-Marie
Rafie, Saloomeh
Planchard, David
Besse, Benjamin
Massard, Christophe
Soria, Jean-Charles
Marabelle, Aurelien
CANCER RESEARCH, 2018, 78 (13)
[43] Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors
Cook, Natalie
Blagden, Sarah
Lopez, Juanita
Sarker, Debashis
Greystoke, Alastair
Haris, Noor Md
Kazmi, Farasat
Anam, Kaiser
Franco, Ana Ortego
Pihlak, Rille
Goodwin, Louise
Wilson, David
Phillips, Caroline
Robertson, Jane
Timmis, Helen
Tilston, Craig
Woodcock, Simon A.
Plummer, Ruth
CANCER RESEARCH, 2024, 84 (07)
[44] First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors
Do, Khanh T.
Chow, Laura Quan Man
Reckamp, Karen
Sanborn, Rachel E.
Burris, Howard
Robert, Francisco
Camidge, D. Ross
Steuer, Conor E.
Strickler, John H.
Weise, Amy
Specht, Jennifer M.
Gutierrez, Martin
Haughney, Peter
Hengel, Shawna
Derleth, Christina Louise
Yap, Timothy A.
ONCOLOGIST, 2021, 26 (11) : 925 - +
[45] Safety and Efficacy Results of BonoFill First-in-Human, Phase I/IIa Clinical Trial for the Maxillofacial Indication of Sinus Augmentation and Mandibular Bone Void Filling
Tzur, Ephraim
Ben-David, Dror
Barzilai, Maya Gur
Rozen, Nimrod
Meretzki, Shai
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2021, 79 (04) : 787 - +
[46] Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study
Moore, Kathleen N.
Sabanathan, Dhanusha
Du, Yiqun
Duan, Huaxin
Li, Xiumin
Wang, Feng
Marathe, Omkar
Yang, Hua
Makker, Vicky
Growdon, Whitfield
Coward, Jim
Zhao, Peng
Liu, Liming
Shi, Rong
Liu, Shengxue
Gu, Wei
Qiu, Yang
Zhu, Zhongyuan
Zhang, Jian
Hamilton, Erika P.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
Kuboki, Yasutoshi
Shimizu, Toshio
Yonemori, Kan
Kojima, Takashi
Kondo, Shunsuke
Koganemaru, Shigehiro
Iwasa, Satoru
Harano, Kenichi
Koyama, Takafumi
Lu, Vickie
Zhou, Xiaofei
Niu, Huifeng
Yanai, Tomoko
Garcia-Ribas, Ignacio
Doi, Toshihiko
Yamamoto, Noboru
CANCER RESEARCH COMMUNICATIONS, 2022, 2 (11): : 1426 - 1435
[48] First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.
Hong, David S.
Garrido-Laguna, Ignacio
Krop, Ian E.
Subbiah, Vivek
Werner, Theresa Louise
Cotter, Christine M.
Hamilton, Erika Paige
Velastegui, Karen
Xuan, Dawei
Bugarini, Roberto
Gollerkeri, Ashwin
Burris, Howard A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[49] RESULTSOF THE FIRST-IN-HUMAN CLINICAL TRIAL WITH PERSONALIZED MULTI-TARGET ADOPTIVE CELL THERAPY (ACTOLOG IMA101)
Tsimberidou, Apostolia
Guenther, Kerstin
Alpert, Amir
Andersson, Borje
Coughlin, Zoe
Fritsche, Jens
Hilf, Norbert
Hwu, Patrick
Kalra, Mamta
Kuttruff-Coqui, Sabrina
Maurer, Dominik
Mendrzyk, Regina
Mohamed, Ali
Norris, Becky
Nowak, Anna
Ort, Rita
Reinhardt, Carsten
Richter, Fabian
Satelli, Arun
Schoor, Oliver
Sieger, Kerry
Singh, Harpreet
Vining, David
Wagner, Claudia
Weinschenk, Toni
Yee, Cassian
Walter, Steffen
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A179 - A179
[50] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
Bendell, Johanna C.
Patel, Manish R.
Moore, Kathleen N.
Chua, Cynthia C.
Arkenau, Hendrik-Tobias
Dukart, Gary
Harrow, Kim
Liang, Chris
ONCOLOGIST, 2019, 24 (04) : 455 - E121

← 1 2 3 4 5 →